on The Platform Group AG (isin : DE000A2QEFA1)
The Platform Group Pursues Pharmaceutical Acquisition and Bond Issue
The Platform Group AG, based in Düsseldorf, is negotiating the acquisition of three companies operating in the pharmaceutical platform sector. The companies are located in Germany, Austria, and the Czech Republic. The Group has been involved in pharmaceuticals through its participation in ApoNow since 2021 and aims to significantly expand this sector. Letters of intent were signed in August 2025, and the company expects to finalize purchase agreements by September 2025.
Post-acquisition, TPG anticipates additional annual revenue in the low three-digit million-euro range, with an EBITDA margin of approximately 4-6%. The total purchase price is expected to be in the double-digit million-euro range. To finance these transactions, TPG may increase its existing corporate bond 2024/2028.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Platform Group AG news